cyc 202 has been researched along with indirubin-5-sulfonate in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (indirubin-5-sulfonate) | Trials (indirubin-5-sulfonate) | Recent Studies (post-2010) (indirubin-5-sulfonate) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 5 | 0 | 2 |
| Protein | Taxonomy | cyc 202 (IC50) | indirubin-5-sulfonate (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.4 | |
| Insulin receptor | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.04 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.2667 | |
| Cyclin-A2 | Homo sapiens (human) | 0.035 | |
| Kit ligand | Homo sapiens (human) | 0.4 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.3 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.1784 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.065 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.065 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akula, N; Pattabiraman, N; Sridhar, J | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
2 review(s) available for cyc 202 and indirubin-5-sulfonate
| Article | Year |
|---|---|
Selectivity and potency of cyclin-dependent kinase inhibitors.
Topics: Animals; Binding Sites; Cyclin-Dependent Kinases; Humans; Protein Kinase Inhibitors; Signal Transduction | 2006 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |